EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Effectiveness and Safety of Baricitinib for Juvenile Idiopathic Arthritis–Associated Uveitis or Chronic Anterior Antinuclear Antibody–Positive Uveitis

Athimalaipet V Ramanan iD, Catherine M Guly, Gabriele Simonini, Stuart Y Keller, Priyanka Sen, Thorsten Holzkaemper, Joana Araújo, Pierre Quartier

Arthritis Care & Research · 2026

DOI: 10.1002/acr.25644 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arthritis Care & Research, 2026. Verfasst von Athimalaipet V Ramanan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Royal Hospital for Children and Translational Health Sciences, Bristol, United Kingdom. Hauptthemen laut MEDLINE: Azetidines, Sulfonamides, Arthritis, Juvenile, Antibodies, Antinuclear. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy and safety of baricitinib in pediatric patients with active juvenile idiopathic arthritis–associated uveitis (JIA‐U) or chronic anterior antinuclear antibody–positive uveitis, who had an inadequate response to methotrexate (MTX) or biologic disease‐modifying antirheumatic drugs (bDMARDs).

Methods

JUVE‐BRIGHT was an open‐label, active‐controlled phase‐3 multicenter trial that used a novel design, including 1:1 randomization to an active reference arm. The primary efficacy endpoint was the proportion of responders at week 24 (W24), defined according to the Standardization of Uveitis Nomenclature (SUN) criteria as a two‐step decrease in the level of inflammation (anterior chamber cells) or decrease to zero through W24 in the most severely affected eye at baseline. Study success was based on a prespecified Bayesian success rule: the study was deemed successful if there was >80% posterior probability that the baricitinib SUN criteria response rate at W24 was at least 57%.

Results

This study enrolled 30 pediatric patients. The study primary endpoint was not met. In the baricitinib group, 36.8% of MTX–inadequate responder (MTX‐IR) and bDMARD‐IR patients and 20% of MTX‐IR patients achieved a two‐step decrease in SUN criteria at W24. Eight patients (33.3%) achieved a response at W24, resulting in 1.03% posterior probability of a response rate of >57%. Safety data were consistent with the established safety profile in other baricitinib indications in pediatric and adult patients.

Conclusion

Although the primary endpoint was not met, the data provide important information on baricitinib for the treatment of children with JIA‐U refractory to both MTX and bDMARDs. Baricitinib safety profile in this study was consistent with previous studies in children and adults with other diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzetidinesSulfonamidesArthritis, JuvenileAntibodies, AntinuclearPyrazolesUveitisHumansPurinesMaleFemaleChildTreatment OutcomeAdolescentAntirheumatic AgentsChild, PreschoolChronic DiseaseMethotrexate

Substanzen

baricitinibPurinesAzetidinesSulfonamidesAntibodies, AntinuclearPyrazolesAntirheumatic AgentsMethotrexate

Autor:innen und Institutionen

  • Bristol Royal Hospital for Children and Translational Health Sciences, Bristol, United Kingdom.
  • Bristol Eye Hospital, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom.
  • ERN ReConnet Center, Meyer Children's Hospital IRCCS and University of Florence, Florence, Italy.
  • Eli Lilly and Company, Indianapolis, Indiana.
  • RAISE Reference Centre for Rare Diseases, Necker-Enfants Malades Hospital, Assistance Publique-Hopitaux de Paris and Université Paris-cité, Paris, France.

ORCID-Profile: Athimalaipet V Ramanan

Förderung

  • Eli Lilly and Company

Zitieren

APA

Ramanan, A. V., Guly, C. M., Simonini, G., Keller, S. Y., Sen, P., Holzkaemper, T., Araújo, J., & Quartier, P. (2026). Effectiveness and Safety of Baricitinib for Juvenile Idiopathic Arthritis–Associated Uveitis or Chronic Anterior Antinuclear Antibody–Positive Uveitis. Arthritis Care & Research. https://doi.org/10.1002/acr.25644

Vancouver

Ramanan AV, Guly CM, Simonini G, Keller SY, Sen P, Holzkaemper T, et al. Effectiveness and Safety of Baricitinib for Juvenile Idiopathic Arthritis–Associated Uveitis or Chronic Anterior Antinuclear Antibody–Positive Uveitis. Arthritis Care & Research. 2026. doi:10.1002/acr.25644

BibTeX
@article{Ramanan2026,
  author = {Ramanan, Athimalaipet V and Guly, Catherine M and Simonini, Gabriele and Keller, Stuart Y and Sen, Priyanka and Holzkaemper, Thorsten and Araújo, Joana and Quartier, Pierre},
  title = {Effectiveness and Safety of Baricitinib for Juvenile Idiopathic Arthritis–Associated Uveitis or Chronic Anterior Antinuclear Antibody–Positive Uveitis},
  journal = {Arthritis Care & Research},
  year = {2026},
  doi = {10.1002/acr.25644}
}
Kostenlos starten →